Compare Adaptive Biotechnologies Corp (ADPT) vs BHP Billiton Limited (BHP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs BHP Billiton Limited — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while BHP Billiton Limited trades at $78.3 (market cap $206.17B). The key difference: BHP Billiton Limited is far larger — about 61.9× Adaptive Biotechnologies Corp's market cap, and BHP Billiton Limited pays a 3.32% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | BHP | |
|---|---|---|
Market Cap | $3.33B | $206.17B |
Sector | Health | Basic Materials |
52-Week High | $22.37 | $93.15 |
52-Week Low | $10.24 | $49.36 |
Enterprise Value | $3.19B | $220.38B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
BHP trades at $80.23, down 3.72% over the past 24 hours, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2025 EPS of $2.12, beating expectations, but missed in Q4 2025. Recent news includes a $2.3 billion writedown at the Jansen potash project and leadership changes under incoming CEO Brandon Craig. Financials show strong profitability with an 18.97% net income margin and $20.67B in operating cash flow for 2024.
BHP's outlook is supported by robust cash flows and strategic focus on copper, but faces risks from cost overruns and labor disputes. Analyst consensus is mixed with 22.58% buy ratings. The stock presents a value opportunity with a P/E of 20.77, though investors should monitor execution on growth projects and commodity price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About BHP Billiton Limited
BHP Group Limited operates as a mining company. The Company engages in the exploration, development, production, and processing of iron ore, metallurgical coal, and copper. BHP Group serves customers worldwide.
Read more on BHP →
